ALX Oncology Holdings Inc. Forecasted to Earn FY2022 Earnings of ($3.23) Per Share (NASDAQ:ALXO)

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Rating) – Stock analysts at Cantor Fitzgerald issued their FY2022 earnings per share estimates for ALX Oncology in a research report issued on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($3.23) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.94) per share. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2023 earnings at ($3.93) EPS.

ALXO has been the subject of several other research reports. Credit Suisse Group dropped their target price on ALX Oncology from $43.00 to $38.00 and set an “outperform” rating for the company in a research report on Tuesday, August 9th. Stifel Nicolaus dropped their target price on ALX Oncology from $35.00 to $16.00 in a research report on Monday, June 6th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $39.83.

ALX Oncology Price Performance

Shares of NASDAQ:ALXO opened at $10.58 on Friday. ALX Oncology has a 1 year low of $5.82 and a 1 year high of $79.00. The business has a 50 day simple moving average of $12.29 and a two-hundred day simple moving average of $12.23. The firm has a market capitalization of $431.10 million, a PE ratio of -3.89 and a beta of 1.84.

Institutional Trading of ALX Oncology

A number of large investors have recently modified their holdings of ALXO. State Street Corp boosted its holdings in shares of ALX Oncology by 47.9% in the first quarter. State Street Corp now owns 2,133,744 shares of the company’s stock valued at $36,060,000 after purchasing an additional 691,410 shares during the period. FMR LLC boosted its holdings in shares of ALX Oncology by 12.0% in the second quarter. FMR LLC now owns 3,986,214 shares of the company’s stock valued at $32,248,000 after purchasing an additional 427,260 shares during the period. Federated Hermes Inc. boosted its holdings in shares of ALX Oncology by 744.2% in the second quarter. Federated Hermes Inc. now owns 456,753 shares of the company’s stock valued at $3,695,000 after purchasing an additional 402,646 shares during the period. Millennium Management LLC boosted its holdings in shares of ALX Oncology by 1,161.4% in the second quarter. Millennium Management LLC now owns 429,280 shares of the company’s stock valued at $3,473,000 after purchasing an additional 395,248 shares during the period. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of ALX Oncology in the second quarter valued at approximately $1,515,000. Hedge funds and other institutional investors own 88.98% of the company’s stock.

About ALX Oncology

(Get Rating)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.

Read More

Earnings History and Estimates for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.